Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Change in Account Payables (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Change in Account Payables for 4 consecutive years, with -$2.0 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 934.69% to -$2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $471000.0 through Dec 2025, down 31.34% year-over-year, with the annual reading at $471000.0 for FY2025, 31.34% down from the prior year.
  • Change in Account Payables for Q4 2025 was -$2.0 million at Day One Biopharmaceuticals, down from $688000.0 in the prior quarter.
  • The five-year high for Change in Account Payables was $4.4 million in Q1 2023, with the low at -$3.7 million in Q4 2022.
  • Average Change in Account Payables over 4 years is $124312.5, with a median of -$168000.0 recorded in 2022.
  • The sharpest move saw Change in Account Payables skyrocketed 2348.65% in 2024, then plummeted 934.69% in 2025.
  • Over 4 years, Change in Account Payables stood at -$3.7 million in 2022, then surged by 78.05% to -$815000.0 in 2023, then soared by 130.06% to $245000.0 in 2024, then tumbled by 934.69% to -$2.0 million in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$2.0 million, $688000.0, and $2.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.